Centanafadine HCl Polymorph Form CN1 Stability and Processing
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
There is a need for additional solid state forms of Centanafadine, including polymorphs and solvates, to improve processing properties, stability, and bioavailability for the treatment of attention-deficit hyperactivity disorder (ADHD).
Innovation Solution
A crystalline polymorph of Centanafadine HCl, designated Form CN1, is developed, characterized by specific X-ray powder diffraction patterns and solid state 13C NMR spectra, which can be used to prepare other solid state forms and pharmaceutical compositions, enhancing properties such as solubility and stability.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If existing solid state forms of Centanafadine are used, then the basic therapeutic function is achieved, but processing properties and stability are insufficient
Solution Approach 1:
The patent applies parameter changes by discovering and characterizing a new polymorphic form (Form I) of Centanafadine HCl with specific crystal structure parameters. This polymorph exhibits improved stability and processing properties compared to previously known forms, directly resolving the contradiction between reliability and ease of manufacture through fundamental changes in the solid-state parameters of the active pharmaceutical ingredient.
2Productivity
If new solid state forms are discovered, then processing and stability properties improve, but formulation complexity increases
Solution Approach 1:
The patent applies local quality by providing detailed, localized characterization data for specific polymorphic forms (XRPD patterns, DSC curves, solid-state NMR spectra) that define the unique properties of each form. This allows formulation scientists to select and work with specific forms having locally optimized properties without needing to understand or manage all possible polymorphic variations, thereby improving processing characteristics while controlling formulation complexity.
3Reliability
If polymorphic forms with different properties are developed, then bioavailability can be improved, but characterization and quality control difficulty increases
Solution Approach 1:
The patent applies universality by establishing a comprehensive characterization framework using multiple complementary techniques (XRPD, DSC, solid-state NMR) that can universally identify and differentiate polymorphic forms. This multi-functional approach allows for improved bioavailability through polymorph selection while simultaneously providing robust, standardized methods for detection and quality control, thereby resolving the contradiction between improved performance and increased characterization difficulty.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The crystalline polymorph of Centanafadine HCl Form CN1 provides improved solubility, stability, and processing characteristics, enabling effective pharmaceutical compositions for treating ADHD, with potential for better bioavailability and extended shelf-life.
Implementation Method 1
characterized by specific X-ray powder diffraction patterns
Implementation Method 2
X-ray powder diffraction patterns
Implementation Method 3
solid state 13C NMR spectra
Data Source
AI summary
The present disclosure encompasses a solid state form of Centanafadine HCl, processes for preparation thereof, and pharmaceutical compositions thereof.